MarAprMayJunJul
↩ TodayMon23Mar
Tue24Mar
Wed25Mar
Thu26Mar
Fri27Mar
Sat28Mar
Sun29Mar
Mon30Mar
Tue31Mar
Wed1Apr
Thu2Apr
Fri3Apr
Sat4Apr
Sun5Apr
Mon6Apr
Tue7Apr
Wed8Apr
Fri10Apr
Sat11Apr
Mon13Apr
Tue14Apr
Wed15Apr
Thu16Apr
Fri17Apr
Sat18Apr
Sun19Apr
Mon20Apr
Tue21Apr
Wed22Apr
Thu23Apr
Fri24Apr
Sat25Apr
Sun26Apr
Mon27Apr
Tue28Apr
Wed29Apr
Thu30Apr
Fri1May
Sat2May
Sun3May
Mon4May
Tue5May
Wed6May
Thu7May
Fri8May
Sat9May
Sun10May
Mon11May
Tue12May
Wed13May
Thu14May
Fri15May
Sat16May
Sun17May
Mon18May
Tue19May
Wed20May
Thu21May
Fri22May
Sat23May
Sun24May
Mon25May
Tue26May
Wed27May
Thu28May
Fri29May
Sat30May
Sun31May
Mon1Jun
Tue2Jun
Wed3Jun
Thu4Jun
Fri5Jun
Sat6Jun
Sun7Jun
Mon8Jun
Tue9Jun
Wed10Jun
Thu11Jun
Fri12Jun
Sat13Jun
Sun14Jun
Mon15Jun
Tue16Jun
Wed17Jun
Thu18Jun
Fri19Jun
Sat20Jun
Sun21Jun
Mon22Jun
Wed24Jun
Thu25Jun
Fri26Jun
Sat27Jun
Sun28Jun
Mon29Jun
Wed1Jul
Thu2Jul
Fri3Jul
Sat4Jul
Sun5Jul
Mon6Jul
Tue7Jul
Wed8Jul
Thu9Jul
Fri10Jul
Sat11Jul
Sun12Jul
Mon13Jul
Tue14Jul
Wed15Jul
Thu16Jul
Fri17Jul
Sat18Jul
Sun19Jul
Mon20Jul
Tue21Jul
Wed22Jul
Thu23Jul
Fri24Jul
Sat25Jul
Sun26Jul
Mon27Jul
Tue28Jul
29 papers read · 26 surfaced · 11 stood out
Today's lead · hematologic_malignancies
Venetoclax in combination with cytarabine with or without idarubicin…
More than half of children with relapsed leukemia achieved complete remission with a venetoclax-chemotherapy combination, with most clearing detectable cancer cells.
Daniels KP, Pounds SB, Wu H et al. · Lancet Haematol
10/10
Impact score
Time to impact (est.)
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
NONE
Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other…
Two newer diabetes drugs show equivalent psychiatric safety while one demonstrates substantially lower suicide-related events than older alternatives.
NONEDynamic immune profiling predicts response to radiation plus…
Immune cell patterns in blood and tumors can predict which kidney cancer patients will respond to radiation plus immunotherapy.
NONEPhase II study of trastuzumab-pkrb plus gedatolisib in patients with…
Targeting a dual pathway escape mechanism in advanced breast cancer produced responses in 43% of heavily pretreated patients with specific mutations.
NONEGermline Multigene Panel Testing in Women With Invasive Lobular Cancer
Genetic testing reveals that lobular breast cancer patients with mutations in key genes face much higher recurrence risk, informing closer monitoring.